source
- German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy resultsImmatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma. Early Phase 1 data in 16 patients…
- Rezera files for IPO to fund NLRP3 peripheral artery disease programRezera, which rebranded from NodThera earlier this year, has entered the queue for an initial public offering. The filing, submitted on Wednesday, is intended to raise capital to support the compa…